Technopark-tenant Medyria raises 3.7 M in Series B financing round

The company recently started the development of the PyCath a novel microcatheter for the invasive diagnosis of ischemic heart conditions, including obstructed and non-obstructed coronary stenosis. The PyCath will be positioned as the only device on the market with pressure and blood flow velocity sensing, with superior usability and reliability, allowing the device to become the best-in-class device for full physiological assessment rapidly.

The first tranche of the Series B financing is a CHF 3.7M equity investment from new and existing investors. The leader of the investment round is Yellowstone Holding AG. The following investors include EFI-Lake Geneva Ventures, Start Angels Network, Zürcher Kantonalbank and a series of independent business angels.

The funds will be used to bring the PyCath system from the current pre-clinical stage to the completion of the design, establishment of the production processes and initialization 510(k) FDA clearance process for access to the US market.